newsfilter
← Latest News
GlobeNewswire·

Successful Commercial Launch of Ryoncil®

NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue from sales of Ryoncil®